- Home
- BRY vs ETON Comparison
BRY vs ETON Comparison
Compare BRY & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- ETON
- Stock Information
- Founded
- BRY 1909
- ETON 2017
- Country
- BRY United States
- ETON United States
- Employees
- BRY N/A
- ETON N/A
- Industry
- BRY Oil & Gas Production
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- BRY Energy
- ETON Health Care
- Exchange
- BRY Nasdaq
- ETON Nasdaq
- Market Cap
- BRY 328.5M
- ETON 329.8M
- IPO Year
- BRY N/A
- ETON 2018
- Fundamental
- Price
- BRY $3.38
- ETON $15.58
- Analyst Decision
- BRY Hold
- ETON Strong Buy
- Analyst Count
- BRY 1
- ETON 3
- Target Price
- BRY $5.00
- ETON $24.00
- AVG Volume (30 Days)
- BRY 947.9K
- ETON 244.0K
- Earning Date
- BRY 03-12-2025
- ETON 05-08-2025
- Dividend Yield
- BRY 17.21%
- ETON N/A
- EPS Growth
- BRY N/A
- ETON N/A
- EPS
- BRY 0.25
- ETON N/A
- Revenue
- BRY $783,841,000.00
- ETON $34,677,000.00
- Revenue This Year
- BRY N/A
- ETON $22.19
- Revenue Next Year
- BRY N/A
- ETON $109.55
- P/E Ratio
- BRY $12.88
- ETON N/A
- Revenue Growth
- BRY N/A
- ETON 5.64
- 52 Week Low
- BRY $3.06
- ETON $3.03
- 52 Week High
- BRY $8.88
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- BRY 34.29
- ETON 53.40
- Support Level
- BRY $3.39
- ETON $14.28
- Resistance Level
- BRY $3.89
- ETON $15.02
- Average True Range (ATR)
- BRY 0.23
- ETON 0.93
- MACD
- BRY -0.04
- ETON -0.00
- Stochastic Oscillator
- BRY 27.00
- ETON 79.52
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.